Three-dimensional environment sensitizes pancreatic cancer cells to the anti-proliferative effect of budesonide by reprogramming energy metabolism.
Eduardo IbelloFederica SaracinoDonatella Delle CaveSilvia BuonaiutoFilomena AmorosoGennaro AndolfiMarco CoronaOmbretta GuardiolaVincenza ColonnaBruno SainzLucia AltucciDario De CesareGilda CobellisEnza LonardoEduardo Jorge PatriarcaCristina D'AnielloGabriella MinchiottiPublished in: Journal of experimental & clinical cancer research : CR (2024)
Collectively, our study reveals that the microenvironment influences the susceptibility of PDAC cells to GCs and provides unprecedented evidence for the anti-proliferative activity of budesonide on PDAC cells in 3D conditions, in vitro and in vivo. Our findings may explain, at least in part, the reason for the lower occurrence of pancreatic cancer in asthmatic patients and suggest a potential suitability of budesonide for clinical trials as a therapeutic approach to fight pancreatic cancer.
Keyphrases
- induced apoptosis
- clinical trial
- cell cycle arrest
- endoplasmic reticulum stress
- end stage renal disease
- stem cells
- newly diagnosed
- ejection fraction
- oxidative stress
- risk assessment
- prognostic factors
- cell death
- lung function
- cell proliferation
- cystic fibrosis
- climate change
- chronic obstructive pulmonary disease
- patient reported